// App-Quantinova.ai

: AKR1D1 knockdown identifies 7α-hydroxy-3-oxo-4-cholestenoic acid (7-HOCA) as a driver of metabolic dysfunction and hepatocellular cancer risk in patients with non-alcoholic fatty liver disease (NAFLD)

Researchers

Presenter

  • Nikolaos Nikolaou

Principal Investigators

  • Anastasia Arvaniti

  • Fabio Sanna

  • Ragazzon da Conceiao

  • Niall Dempster

  • Laura Gathercole

  • Jeremy Tomlinson

Medical Centers

  • University of Cambridge, Department of Oncology, Cambridge, United Kingdom

  • University of Oxford, Oxford Centre for Diabetes, Endocrinology and Metabolism, Oxford, United Kingdom

  • Oxford Brookes University, Department of Biological and Medical Sciences, Oxford, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Gastroenterology (GU)

Disease

  • Nonalcoholic fatty liver disease

  • Liver cancer

  • Fatty Liver Disease

  • Cirrhosis

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved